VivoSeq
Hematology

Bone Marrow Transplantation

100

Pipeline Programs↗

4

Active Trials↗

38

Companies Involved↗

Bone Marrow Transplantation is a moderately active landscape with 100 programs across 38 companies. The most active players are Iovance Biotherapeutics, Inc., Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Amgen. 3 therapies are approved with 29 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

0/100

Mech. Concentration

8/100

Completion Rate

83/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iovance Biotherapeutics, Inc.

1 program

Phase 1C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 1U

US Oncology Research

1 program

Phase 1A

Avyxa

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical10

Sargramostim

Sanofi

Methylprednisolone

Pfizer

Cyclophosphamide

Baxter Healthcare Corporation

Clofarabine

Genzyme, a Sanofi Company

Campath 1h

Mario Negri Institute for Pharmacological Research

Phase 110

Filgrastim

Eastern Cooperative Oncology Group

Aldesleukin

Iovance Biotherapeutics, Inc.

Temozolomide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Denosumab

Amgen

Azacitidine

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 248

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Carboplatin

Avyxa

Leucovorin Calcium

Eastern Cooperative Oncology Group

Maraviroc

GSK

Sirolimus

Prism Pharmaceuticals

Phase 329

Itraconazole

Sebela Pharmaceuticals Development LLC

Dexamethasone

Aspen Global Incorporated

Ibrutinib

Pharmacyclics LLC.

Cytarabine

Teva

Methotrexate

Alnylam Pharmaceuticals

Approved3

Thiotepa

Alnylam Pharmaceuticals

Drotrecogin Alfa Activated

Eli Lilly

Inactivated Split-Virus Influenza Vaccine

The Cleveland Clinic

Analysis

Modality Breakdown

83%

Small molecule

91 of 109 classified programs — the dominant modality here.

17%ALL OTHERSProtein / enzyme66%Monoclonal antibody44%Cell therapy44%Vaccine22%Antibody–drug conjugate1<1%Peptide1<1%

Small molecule leads; the ring shows all 109 classified programs, each share of the total. Modality classified for 100% of 117 pipeline programs.

Analysis

Trial Status

104

clinical trials

Completed71 · 68%
Unknown status14 · 13%
Terminated12 · 12%
Withdrawn3 · 3%
Active, not recruiting2 · 2%
Recruiting2 · 2%

Clinical Trials

Trial Activity

104 trials

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
Recruiting·—·Phase 1/2·NCT03500731·8 enrolled
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT04959175·320 enrolled
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Active, not recruiting·—·Phase 2·NCT01659606·40 enrolled
Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)
Active, not recruiting·—·Phase 1·NCT04248192·8 enrolled
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00003883·578 enrolled
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome
Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00002547·280 enrolled
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002502
Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00801632·5 enrolled
Effectiveness of Azithromycin Therapy in Improvement of Symptoms and Lung Function in Patients With Bronchiolitis Obliterans After Bone Marrow Transplantation
Completed·HHospital Authority, Hong Kong·N/A·NCT00563251·30 enrolled
Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)
Completed·UUniversity of California, San Francisco·N/A·NCT03609814·30 enrolled
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia
Completed·MMedical Research Council·Phase 3·NCT00003436·2,000 enrolled
Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma
Completed·VVirginia Commonwealth University·Phase 2/3·NCT00003187·19 enrolled
Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission
Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00002534
Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors
Completed·UUNICANCER·Phase 3·NCT00002566·280 enrolled
Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma
Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003195
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)